Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the <scp>BioDay</scp> registry - Concepedia

Concepedia

Publication | Open Access

Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the <scp>BioDay</scp> registry

DOI Full Paper Access

27

Citations

22

References

2022

Year

Esmé Kamphuis, Celeste M. Boesjes, Laura Loman, Daphne S. Bakker, Mila Poelhekken, Nicolaas P. A. Zuithoff, Marijke Kamsteeg, Geertruida L. E. Romeijn, Femke van Wijk, Marjolein de Bruin‐Weller,

Pediatric Allergy and Immunology

Abstract

Dupilumab treatment significantly improved disease severity and disease-associated symptoms and decreased severity-associated serum biomarkers in pediatric AD patients in daily practice.

References

	Year	Citations

Page 1